Skip to main content

Clinical Trials Search

Tennessee Oncology is home to one of the leading clinical trial networks in the country. We offer a broad menu of trial opportunities in every phase of treatment. Use the search below to discover and learn more about our clinical trials:




42 Results

NCT04657068

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety,…

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Condition: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Status: Open to Enrollment
Phase: Phase I/IIa
Location: Chattanooga
Protocol: ART0380C001

View Details
NCT04140526

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent…

Condition: Adenoid Cystic Carcinoma, Advanced Solid Tumor, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Carcinoma, Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreas Cancer, Salivary Gland Cancer, Sarcomas, Small Cell Lung Cancer, Urothelial Carcinoma
Status: Open to Enrollment
Phase: Phase IA/IB/II
Location: Chattanooga
Protocol: ONC-392-001

View Details
NCT04046445

An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study…

Condition: Colorectal Cancer, Liver Metastasis Colon Cancer, Metastatic Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
Status: Open to Enrollment
Phase: Phase 1
Location: Chattanooga
Protocol: BI 754091

View Details
NCT05827016

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing…

Condition: Multiple Myeloma
Status: Open to Enrollment
Phase: Phase 3
Location: Nashville
Protocol: IM048022

View Details
NCT04975997

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide,…

Condition: Multiple Myeloma
Status: Open to Enrollment
Phase: Phase 3
Location: Nashville
Protocol: CC-220- MM-002

View Details
NCT04270409

A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab…

Condition: Plasma Cell Myeloma
Status: Open to Enrollment
Phase: Phase 3
Location: Nashville
Protocol: EFC15992

View Details
NCT05207670

An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy,…

Condition: Non-Hodgkin Lymphoma
Status: Open to Enrollment
Phase: Phase 2
Location: Nashville
Protocol: ML43389

View Details
NCT04561206

A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab Without…

Condition: Relapsed Classic Hodgkin Lymphoma
Status: Open to Enrollment
Phase: Phase 2
Location: Nashville
Protocol: 20147

View Details
NCT04014205

A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine…

Condition: B-cell Malignancies
Status: Open to Enrollment
Phase: Phase I/IIa
Location: Nashville
Protocol: ICP-CL-00107

View Details
NCT05207670

An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy,…

Condition: Non-Hodgkin Lymphoma
Status: Open to Enrollment
Phase: Phase 2
Location: Chattanooga
Protocol: ML43389

View Details
NCT05688475

Continuing Treatment for Participants Who Have Participated in a Prior…

Condition: Non-Hodgkin Lymphoma
Status: Open to Enrollment
Phase: Phase 1
Location: Nashville
Protocol: CA0921000

View Details
NCT02343042

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With…

Condition: Multiple Myeloma
Status: Open to Enrollment
Phase: Phase 1b/2
Location: Nashville
Protocol: KCP-330-017

View Details
NCT04806035

A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination…

Condition: Aggressive Lymphoma, CLL, DLBCL, Follicular Lymphoma, Indolent Lymphoma, Marginal Zone Lymphoma, MCL, Mediastinal Large B-cell Lymphoma, Richter's Transformation, SLL
Status: Open to Enrollment
Phase: Phase 1b
Location: Chattanooga
Protocol: TG-1801-102

View Details
NCT04806035

A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination…

Condition: Aggressive Lymphoma, CLL, DLBCL, Follicular Lymphoma, Indolent Lymphoma, Marginal Zone Lymphoma, MCL, Mediastinal Large B-cell Lymphoma, Richter's Transformation, SLL
Status: Open to Enrollment
Phase: Phase 1b
Location: Nashville
Protocol: TG-1801-102

View Details
NCT04984811

A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor…

Condition: Non-small Cell Lung Cancer
Status: Open to Enrollment
Phase: Phase 2
Location: Chattanooga
Protocol: NIT-119

View Details
NCT04824092

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the…

Condition: Diffuse Large B-Cell Lymphoma
Status: Open to Enrollment
Phase: Phase 3
Location: Nashville
Protocol: MOR208C310

View Details
NCT04464798

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics,…

Condition: Lymphoma
Status: Open to Enrollment
Phase: Phase 1/2
Location: Nashville
Protocol: CC-220-NHL-001

View Details
NCT04224493

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive…

Condition: Follicular Lymphoma, Refractory Follicular Lymphoma, Relapsed/Refractory Follicular Lymphoma
Status: Open to Enrollment
Phase: Phase 1b/3
Location: Nashville
Protocol: EZH-302

View Details
NCT04170283

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens…

Condition: B-cell Malignancies
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: BGB-3111-LTE1

View Details
NCT04170283

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens…

Condition: B-cell Malignancies
Status: Open to Enrollment
Phase: Phase 3
Location: Nashville
Protocol: BGB-3111-LTE1

View Details
NCT05091567

A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in…

Condition: Small Cell Lung Cancer
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: GO43104

View Details
NCT03739710

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master…

Condition: Non-small Cell Lung Cancer
Status: Open to Enrollment
Phase: Phase 2
Location: Chattanooga
Protocol: GSK 205801

View Details
NCT05645692

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig…

Condition: Urothelial Cancer
Status: Open to Enrollment
Phase: Phase 2
Location: Chattanooga
Protocol: BO44157

View Details
NCT05288166

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of…

Condition: Abiraterone Acetate, and Hormone Antagonists, Androgens, Antineoplastic Agents, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cytochrome P-450, Enzyme Inhibitors, Hormonal, Hormone Substitutes, Hormones, Neoplasm Metastasis, Physiological Effects of Drugs, Prednisolone, Prednisone, Prostatic Neoplasms, Steroid Synthesis Inhibitors, Urogenital Neoplasms
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: I3Y-MC-JPEG

View Details
NCT05348577

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy…

Condition: Prostate Cancer
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: D361EC00001

View Details
NCT04381832

Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based…

Condition: Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer, Prostatic Neoplasms
Status: Open to Enrollment
Phase: Phase 1b/2
Location: Chattanooga
Protocol: ARC-6

View Details
NCT05425940

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab…

Condition: Colorectal Cancer
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: XL092-303

View Details
NCT05568095

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab,…

Condition: Advanced Upper Gastrointestinal Tract Adenocarcinoma
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: STAR-221

View Details
NCT04471844

Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz)…

Condition: Glioblastoma Multiforme
Status: Open to Enrollment
Phase: N/A
Location: Chattanooga
Protocol: Novocure_EF-32

View Details
NCT05057494

A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib…

Condition: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Status: Open to Enrollment
Phase: Phase 3
Location: Nashville
Protocol: D8220C00027

View Details
NCT05254743

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus…

Condition: B-cell, Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Small Lymphocytic Lymphoma
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: LOXO-BTK-20030

View Details
NCT03875235

A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study…

Condition: Biliary Tract Neoplasms
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: D933AC00001

View Details
NCT05480306

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab…

Condition: Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer, Colorectal Cancer Metastatic
Status: Open to Enrollment
Phase: Phase 2
Location: Chattanooga
Protocol: DEK-DKK1-P207

View Details
NCT04965493

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib…

Condition: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: LOXO-BTK-20022

View Details
NCT04965493

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib…

Condition: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Status: Open to Enrollment
Phase: Phase 3
Location: Nashville
Protocol: LOXO-BTK-20022

View Details
NCT04116437

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in…

Condition: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Status: Open to Enrollment
Phase: Phase 2
Location: Nashville
Protocol: BGB-3111-215

View Details
NCT05645536

Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast…

Condition: Breast Cancer
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: TOL2506A-EXT

View Details
NCT05629585

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd)…

Condition: Breast Cancer
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: D926XC00001

View Details
NCT04468061

Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With…

Condition: Breast Cancer
Status: Open to Enrollment
Phase: Phase 2
Location: Chattanooga
Protocol: 20-166

View Details
NCT05774951

A Phase III, Open-Label, Randomised Study to Assess the Efficacy…

Condition: Breast Cancer
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: D8531C00002

View Details
NCT04711252

SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833…

Condition: Breast Cancer
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: D8532C00001

View Details
NCT04906395

Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month…

Condition: Breast Cancer
Status: Open to Enrollment
Phase: Phase 3
Location: Chattanooga
Protocol: TOL2506A

View Details